Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -6.8M | 1.4% |
| Cost of Revenue | 6.8M | 1.4% |
| Operating expense | 33M | 9.1% |
| Net Income | -31M | 11% |
| EBITDA | -33M | 10.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 204M | 6% |
| Total Liabilities | 30M | 68.6% |
| Total Equity | 174M | 12.7% |
| Shares Outstanding | 49M | 1.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -20M | 2.2% |
| Cash from investing | 12M | 48.4% |
| Cash from financing | 71,000 | 81.3% |
EPS
Financial Highlights for Cabaletta Bio in Q3 '24
Gross Profit stood at -6.8M, marking a 1.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 6.8M, a -1.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 33M, showing a 9.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -31M, showing a -11% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -33M, showing a -10.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cabaletta Bio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
